Table 3.
Expenditure and number of patients by pharmacological classes.
| Year | Expenditure No. Patients |
Cytotoxic Drugs |
Immunotherapy | Targeted Therapy | Radiopharmaceuticals | Other | Total Antineoplastic Drugs | % Change Previous Year |
|---|---|---|---|---|---|---|---|---|
| 2010 | Expenditure | €2,849,013 | €6,295,413 | €9,144,426 | ||||
| Patients | 1720 | 1 | 487 | 1941 | ||||
| 2011 | Expenditure | €1,948,767 | €5,787,658 | €7,736,424 | −15.40 | |||
| Patients | 1647 | 5 | 377 | 1837 | ||||
| 2012 | Expenditure | €1,856,463 | €4423 | €5,688,042 | €7,548,927 | −2.44 | ||
| Patients | 1771 | 5 | 386 | 1964 | ||||
| 2013 | Expenditure | €1,768,568 | €10,155 | €5,095,094 | €6,873,817 | −8.95 | ||
| Patients | 1811 | 5 | 385 | 2008 | ||||
| 2014 | Expenditure | €1,867,964 | €450,580 | 6,755,288 | €9,073,832 | 32.01 | ||
| Patients | 1804 | 13 | 477 | 2067 | ||||
| 2015 | Expenditure | €2,144,778 | €685,798 | €9,113,317 | €11,943,892 | 31.63 | ||
| Patients | 1911 | 47 | 594 | 2244 | ||||
| 2016 | Expenditure | €2,246,494 | €593.732 | €11,146,186 | €394,908 | €14,351,319 | 20.17 | |
| Patients | 2020 | 49 | 695 | 20 | 2391 | |||
| 2017 | Expenditure | €1,988,765 | €1,311003 | €10,766,721 | €399,352 | €136 | €14,465,977 | 0.80 |
| Patients | 1969 | 65 | 718 | 17 | 3 | 2376 | ||
| 2018 | Expenditure | €2,116,242 | €1,798,999 | €13,598,269 | €462,037 | €530 | €17,976,077 | 24.26 |
| Patients | 2045 | 96 | 889 | 17 | 5 | 2543 | ||
| 2019 | Expenditure | €1,985083 | €2,577,195 | €16,317,770 | €400,730 | €626 | €21,281,403 | 18.40 |
| Patients | 2141 | 124 | 1038 | 19 | 4 | 2772 |